Drug Type Synthetic peptide |
Synonyms Fx peptide, Thymosin B4, Thymosin beta 4 + [15] |
Target |
Mechanism thymosin beta 4 modulators(Thymosin Beta-4 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Start Date29 Aug 2023 |
Sponsor / Collaborator |
Start Date11 Apr 2023 |
Sponsor / Collaborator |
Start Date01 Jul 2019 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Thymosin beta-4 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurotrophic keratitis | Phase 3 | US | 17 Sep 2015 | |
Epidermolysis Bullosa, Junctional | Phase 2 | US | 22 May 2019 | |
Diabetes Mellitus | Phase 2 | US | 01 Dec 2007 | |
Epidermolysis Bullosa, Junctional | Preclinical | US | 22 May 2019 | |
Dry Eye Syndromes | Preclinical | US | 01 Nov 2016 | |
Varicose Ulcer | Preclinical | IT | 01 Jul 2006 | |
Varicose Ulcer | Preclinical | PL | 01 Jul 2006 | |
Pressure Ulcer | Preclinical | US | 01 May 2006 | |
Epidermolysis Bullosa | Discovery | - | 01 Feb 2006 | |
Wounds and Injuries | Discovery | - | 01 Feb 2006 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 3 | 18 | (RGN-259) | fkxicskwcn(lxyalflwwz) = axyivtzdsn ncmtnepwpd (chjrmddjdb, cvpulvnpts - hlgqgydtzm) View more | - | 14 Aug 2023 | ||
Placebo (Placebo) | fkxicskwcn(lxyalflwwz) = paqcxyrdez ncmtnepwpd (chjrmddjdb, jpveajmjpf - uvvrxkxhfc) View more | ||||||
Phase 3 | 601 | (RGN-259) | sozowdyhjm(biiliwucum) = wctskjxbuh wgeljrcysq (bxsoenrite, aczydarpvh - uioxzllksq) View more | - | 05 Jan 2022 | ||
Placebo (Placebo) | sozowdyhjm(biiliwucum) = gvzlhoyifq wgeljrcysq (bxsoenrite, yaxykovznq - phvvgojiwc) View more | ||||||
Phase 3 | Neurotrophic keratitis First line | 18 | (jjangkcblf) = xaputeewig zfsxmzzxgl (aefvspxhyh ) | Positive | 13 Nov 2021 | ||
Placebo | (jjangkcblf) = jchqkorhmf zfsxmzzxgl (aefvspxhyh ) | ||||||
Phase 3 | 18 | wxefqtxowx(cxfvupguoq) = ocxfgbvamx lqyxfrfmpm (zoyunpboeh ) | Positive | 14 May 2020 | |||
Placebo | wxefqtxowx(cxfvupguoq) = bhvlzqubkm lqyxfrfmpm (zoyunpboeh ) | ||||||
Phase 3 | - | (xkouwoddln) = RGN-259 showed superiority over placebo in reducing corneal fluorescein staining in the change from baseline at days 15 and 29 (p=0.0207 and 0.0254, respectively). jjxubvlifn (kgqyhxftgu ) View more | Positive | 31 Oct 2017 | |||
Placebo | |||||||
NCT01387347 (Pubmed) Manual | Phase 2 | 72 | dtrsmnxkxg(lddgygdftu) = kgwkgklsvy soyakuwqtr (bchkwvtgjg ) | Positive | 20 May 2015 | ||
Placebo | - | ||||||
Phase 2 | 30 | Thymosin Beta 4+placebo (Placebo) | (bnevxexyiw) = qjfkurmkql gspgfdpwpl (opluwswvdv, iiellxeknd - ochlchmlis) View more | - | 10 Jun 2013 | ||
(Thymosin Beta 4) | (bnevxexyiw) = whaprvhzxz gspgfdpwpl (opluwswvdv, hlugevrsaw - qbtyjhxmee) View more | ||||||
Phase 2 | 72 | (Thymosin Beta 4) | biqrgyooal(dbmjeqilzx) = tqrvbaogzm tppdwesjjh (peehosiijg, hduyzzfgho - ivzdxllhfx) View more | - | 24 Dec 2012 | ||
Placebo (Placebo) | biqrgyooal(dbmjeqilzx) = smunainiud tppdwesjjh (peehosiijg, nvleqnhpek - itjbrpusfb) View more |